Amgen severs 14-year Cytokinetics partnership, bailing on omecamtiv after mixed PhIII results

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 23, 2020 at 10:22 PM.

  1. #1 cafead, Nov 23, 2020 at 10:22 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,979
    Likes Received:
    3
    via Amgen is shrugging off a 14-year development alliance and the tens of millions of dollars spent to develop a new heart drug at Cytokinetics after a Phase III trial turned up weak data — leaving Cytokinetics to soldier on alone.

    article source
     
    Quote

Reply to Thread